Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].

  2. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States. … Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions.

  4. Drug

    Heptabarbital

    go.drugbank.com/drugs/DB01354
    Experimental

    Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

  5. Drug

    Vanadium

    go.drugbank.com/drugs/DB13971
    Approved

    Mixtures: Extra Once A Day, Maximum Once A Day
  6. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is designed for intravenous administration for acute use … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Modafinil

    go.drugbank.com/drugs/DB00745
    ApprovedInvestigational

    Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  8. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. … It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid).

  9. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] … [L8453,L8459] It was first approved for use in the United States in 2014.

  10. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    [L12099] Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. … granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.